Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa 04 March 2020
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters 10 December 2019
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa 20 November 2019
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease 17 October 2019
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence 03 October 2019
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine 06 September 2019
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention 11 July 2019
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio 01 July 2019
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® 07 June 2019
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial 03 June 2019
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment 22 May 2019
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care 14 May 2019
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians 07 May 2019
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off 09 April 2019
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre 03 April 2019
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW 11 March 2019
Novartis receives European Commission approval for self-administration of Xolair® across all indications 13 December 2018
Novartis rises to second place in 2018 Access to Medicine Index 22 November 2018
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH 29 October 2018
Alcon to develop SMART Suite digital health platform for cataract surgery 23 October 2018